Metabolic therapeutics in angina pectoris: History revisited with perhexiline

Sally Inglis, Simon Stewart

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)


The ever-increasing burden of ischaemic heart disease and its common manifestation chronic angina pectoris calls for the exploration of other treatment options for those patients who despite the maximum conventional pharmacological and surgical interventions continue to suffer. Such exploration has led to the increasing use of new metabolically acting antianginal agents and the re-emergence of an old and somewhat forgotten pharmacological agent, perhexiline maleate. This review aims to update the cardiac nurse with knowledge to manage the care a patient receiving perhexiline maleate treatment and provide a brief review of three new metabolic agents: trimetazidine, ranolazine and etomoxir.

Original languageEnglish
Pages (from-to)175-184
Number of pages10
JournalEuropean Journal of Cardiovascular Nursing
Issue number2
Publication statusPublished - 1 Jun 2006
Externally publishedYes


  • Etomoxir
  • Nursing management
  • Perhexiline
  • Pharmacology
  • Ranolazine
  • Refractory angina
  • Trimetazidine


Dive into the research topics of 'Metabolic therapeutics in angina pectoris: History revisited with perhexiline'. Together they form a unique fingerprint.

Cite this